The California Institute for Regenerative Medicine (CIRM) recently approved nearly $31 million in funding, further cementing our commitment to advancing the field of regenerative medicine. This substantial investment aims to drive clinical research targeting various cancers and eye diseases. CIRM’s dedication to fostering innovative treatments is demonstrated through its clinical program, which funds eligible stem … Continue reading CIRM’s $31 million boost for cancer and eye disease research
News
CIRM awards $25 million for discovery and clinical research, infrastructure programs
Stock image of a researcher The California Institute for Regenerative Medicine (CIRM) has recently approved awarding $25 million to fund multiple projects across discovery research, clinical research, and infrastructure programs.This funding will support 11 projects under CIRM's Foundation Awards Program, which aims to drive rigorous studies addressing critical basic knowledge gaps in the biology of … Continue reading CIRM awards $25 million for discovery and clinical research, infrastructure programs
CIRM approves $2.5 million to establish a Patient Support Program
Hataalii Tiisyatonii Begay (HT) participated in a CIRM-funded clinical trial at UCSF for Artemis-SCID, a condition that can be life-threatening or fatal. Photo courtesy Barbara Ries / UCSF. The California Institute for Regenerative Medicine (CIRM) funds innovative cell and gene therapy research and educational programs to advance regenerative medicine in the Golden State. Just as … Continue reading CIRM approves $2.5 million to establish a Patient Support Program
CIRM celebrates landmark 100+ clinical trial awards
Photo credit: Barbara Ries for UCSF, Jaquell Chandler, and OHSU/Christine Torres Hicks The California Institute for Regenerative Medicine (CIRM), California’s Stem Cell Agency and the world’s largest institution dedicated to regenerative medicine reached a milestone when it approved funding for its 100th clinical trial. At the February Independent Citizens’ Oversight Committee (ICOC) meeting, the board … Continue reading CIRM celebrates landmark 100+ clinical trial awards
CIRM awards more than $56 million for clinical research aimed at treating Parkinson’s disease, autoimmune conditions and a variety of cancers
The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, awarded $56 million to fund various clinical research aimed at treating Parkinson’s disease, autoimmune conditions and a variety of cancers. The awards will support seven projects—five clinical trials and two preclinical projects—in the Agency’s clinical program which provides funding for … Continue reading CIRM awards more than $56 million for clinical research aimed at treating Parkinson’s disease, autoimmune conditions and a variety of cancers
Neurona Therapeutics Raises $120M Financing, Cell Therapy Shows Positive Outcomes in CIRM-Funded Trial
Photo Courtesy of Neurona Therapeutics/Curtis Myers Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, recently announced the successful completion of a $120 million financing. Neurona’s financial success is an encouraging sign for the stem cell and gene therapy sector, highlighting partnerships with investors and public organizations … Continue reading Neurona Therapeutics Raises $120M Financing, Cell Therapy Shows Positive Outcomes in CIRM-Funded Trial
CIRM Joins World AIDS Day Campaign, Commits $104 Million for HIV Research
John A. Zaia, MD, of Beckman Research Institute of City of Hope This year marks the 35th commemoration of World AIDS Day, a global event that aims to end human immunodeficiency virus (HIV) related stigma, honor people lost to the disease, and reaffirm the commitment to ensuring HIV is no longer a public health threat. … Continue reading CIRM Joins World AIDS Day Campaign, Commits $104 Million for HIV Research
FDA Accepts Application for CIRM-Funded Program Aimed to Treat Rare Pediatric Disease
The California Institute for Regenerative Medicine (CIRM) congratulates Rocket Pharmaceuticals, Inc, a leading late-stage biotechnology company. The company received U.S. FDA acceptance of the Biologics License Application (BLA) and Priority Review for RP-L201 (marnetegragene autotemcel). CIRM helped support the development of this entiviral vector (LV)-based gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I). What BLA … Continue reading FDA Accepts Application for CIRM-Funded Program Aimed to Treat Rare Pediatric Disease
CIRM invests nearly $44 million to advance regenerative medicine research and manufacturing in California
Novoglia, Inc. was awarded a $1.4 million award to support the development of a cell therapy for the treatment of ALSP. Pictured are Novoglia, Inc. co-founders Sunil Gandhi, PhD, Robert Spitale, PhD, and Mathew Blurton-Jones, PhD. September 29, 2023 South San Francisco, CA – The California Institute for Regenerative Medicine (CIRM), the world’s largest institution … Continue reading CIRM invests nearly $44 million to advance regenerative medicine research and manufacturing in California
CIRM invests $50 million in clinical research, including trial for vision loss
The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, today awarded $50.1 million to fund clinical-stage research projects aimed at advancing stem cell and gene therapy treatments for a variety conditions ranging from neurodegenerative diseases and blood cancers to HIV/AIDS. The awards will support six projects in the Agency’s … Continue reading CIRM invests $50 million in clinical research, including trial for vision loss